Reduced fecal intestinal alkaline phosphatase is associated with gestational diabetes mellitus: A hospital-based multicentre cross-sectional study in Bangladesh

This hospital-based multicentre cross-sectional study in Bangladesh reveals that reduced fecal intestinal alkaline phosphatase levels are independently associated with gestational diabetes mellitus, suggesting a potential role for gut-derived metabolic dysregulation in the condition despite the marker's current limitation as a standalone diagnostic tool.

The Gist

The Big Picture: A Broken Gut Filter

Imagine your gut (intestines) is a busy border crossing between the outside world and your body. Usually, this border has a very strict security guard who stops bad invaders (like toxic bacteria) from sneaking into your bloodstream.

This study looked at a specific enzyme called Intestinal Alkaline Phosphatase (IAP). Think of IAP as the "security guard" or a "clean-up crew" living in your gut. Its main job is to neutralize toxins (specifically something called lipopolysaccharides, or LPS) that come from bacteria. If the guard is strong, the toxins are neutralized, and your body stays calm. If the guard is weak or missing, the toxins slip through, causing low-level inflammation and messing up how your body handles sugar.

The Study: What Did They Do?

Researchers in Bangladesh wanted to see if this "security guard" (IAP) behaves differently in pregnant women who develop Gestational Diabetes (GDM) compared to those who don't.

• The Participants: They looked at 198 pregnant women.
• The Groups:
  • Group A (55 women): Had GDM (high blood sugar during pregnancy).
  • Group B (143 women): Had normal blood sugar (NGT).
• The Test: Instead of just checking blood sugar, they asked the women to provide a stool sample. They measured how much "security guard" (IAP) was in the poop.

The Findings: The Guard Was Missing

The results were clear:

1. Low Numbers: The women with Gestational Diabetes had significantly lower levels of IAP in their stool compared to the women with normal blood sugar.
   • Analogy: It's like finding a fortress with only a few sleepy guards on duty, while the healthy fortress has a full, alert team.
2. The Connection: Even after the researchers accounted for other factors like body weight (BMI) and whether the woman had GDM in a previous pregnancy, the low IAP levels were still strongly linked to having GDM.
   • Analogy: Even if you know the woman is overweight (a known risk factor), the fact that her "security guard" is missing adds extra risk. The missing guard is a problem on its own.
3. The Gradient: The lower the IAP level, the more likely the woman was to have GDM.
   • Analogy: It's like a dimmer switch. As the light (IAP) gets dimmer, the risk of the house catching fire (GDM) gets brighter.

Can We Use This to Diagnose GDM?

The researchers tested if measuring IAP could replace the standard blood sugar test (the Oral Glucose Tolerance Test).

• The Result: Not quite. The test wasn't perfect at telling the two groups apart on its own (it had a "modest" ability to distinguish them).
• The Silver Lining: However, the test was very good at catching potential cases (high sensitivity).
  • Analogy: Imagine a metal detector at an airport. This IAP test is like a detector that beeps for almost everyone who might have a weapon, even if it sometimes beeps for people who are just carrying a belt buckle. It's great for making sure you don't miss anyone, but you need a second, more precise check to confirm who actually has the weapon.

What Does This Mean?

The study suggests that Gestational Diabetes isn't just about hormones or weight; it might also be about a broken gut barrier. When the "clean-up crew" (IAP) is weak, toxins get into the blood, causing inflammation that makes it harder for the body to manage sugar during pregnancy.

Important Note: The authors are careful to say this is a new discovery, not a new medical rule yet. They found a link, but they did not prove that fixing the IAP will cure GDM, nor do they recommend using this stool test as a standard diagnostic tool right now. They suggest it could be a helpful "extra clue" for doctors to identify women who might be at higher risk, but more research is needed to confirm how it works.

Technical Summary

Technical Summary: Reduced Fecal Intestinal Alkaline Phosphatase and Gestational Diabetes Mellitus

Problem Statement
Gestational diabetes mellitus (GDM) is a prevalent metabolic complication of pregnancy with significant adverse outcomes for both mother and neonate. While the etiology is traditionally attributed to placental hormones exacerbating insulin resistance and beta-cell dysfunction, emerging evidence suggests a role for gut-derived metabolic endotoxemia. Intestinal alkaline phosphatase (IAP), an enzyme critical for maintaining gut barrier integrity and detoxifying lipopolysaccharides (LPS), has been linked to Type 2 Diabetes Mellitus (T2DM) in non-pregnant populations. However, its specific role and levels in the context of GDM remain unexplored. This study addresses the gap in understanding whether fecal IAP deficiency is associated with gestational glucose intolerance.

Methodology
This was a hospital-based, multicentre, cross-sectional analytical study conducted in Bangladesh between March 2024 and September 2025.

• Population: The study recruited 198 pregnant women from three tiers of antenatal care (rural, suburban, and urban) who were undergoing GDM screening.
• Exclusion Criteria: Women with multiple gestations, pre-existing diabetes, acute illnesses, gastrointestinal diseases, or those taking specific medications (e.g., steroids, antibiotics, NSAIDs) were excluded.
• Classification: Participants were classified into two groups based on the 2013 WHO criteria following a 75-g oral glucose tolerance test (OGTT): GDM (n=55) and Normal Glucose Tolerance (NGT; n=143).
• Sample Collection & Analysis: Fasting stool samples were collected and stored at 4°C. Fecal IAP levels were measured using an enzymatic colorimetric assay on an automated biochemistry analyzer. To ensure specificity for intestinal alkaline phosphatase, samples were treated with L-phenylalanine, a specific IAP inhibitor, to distinguish it from other alkaline phosphatase isoforms.
• Statistical Analysis: Comparisons between groups utilized Mann-Whitney U tests for continuous variables and chi-square tests for categorical variables. Logistic regression (univariate and multivariate) was performed to identify independent predictors of GDM, adjusting for confounders such as BMI and history of GDM. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance of fecal IAP.

Key Results

• Demographics: Women with GDM had significantly higher median body weight (62.1 kg vs. 57.5 kg) and BMI (27.0 vs. 24.6 kg/m²) compared to the NGT group. A history of GDM was also significantly more common in the GDM group.
• IAP Levels: The median fecal IAP level was significantly lower in women with GDM compared to those with NGT (23.59 U/g vs. 46.48 U/g; p<0.001).
• Deficiency Grading: A graded relationship was observed between IAP levels and GDM status. Severe IAP deficiency (0–18 U/g) was more prevalent in the GDM group (43.6%) than in the NGT group (24.5%). Conversely, normal IAP levels (>65 U/g) were significantly more common in the NGT group (42.7%) compared to the GDM group (12.7%).
• Multivariate Analysis: After adjusting for BMI and previous GDM history, lower fecal IAP levels remained an independent predictor of GDM (Adjusted Odds Ratio: 0.98 per unit increase; 95% CI 0.97–0.99; p<0.001).
• Diagnostic Performance: ROC analysis yielded an Area Under the Curve (AUC) of 0.676. A threshold of approximately 65 U/g demonstrated high sensitivity (89.1%) but low specificity (42.0%) for identifying GDM.

Significance and Claims
The authors claim this study represents the first investigation into fecal IAP as a potential biomarker for gestational glycemic dysfunction. The primary finding is that reduced fecal IAP is independently associated with GDM, supporting the hypothesis that gut-derived metabolic dysregulation and potential endotoxemia play a role in gestational glucose intolerance.

The paper posits that while fecal IAP measurement lacks the discriminative power to serve as a standalone diagnostic tool for GDM, it may function as a complementary biomarker for risk stratification. The study suggests that IAP deficiency could reflect an under-recognized component of the metabolic disturbances associated with gestational dysglycemia, potentially linking intestinal barrier dysfunction to the pathogenesis of GDM. The authors conclude that prospective studies are necessary to determine the predictive value of fecal IAP and to explore its potential as a therapeutic target, emphasizing that these findings extend the understanding of GDM beyond traditional endocrine pathways to include gut-metabolic axes.